$RXRX 8-K/A SEC Filings

At your request, we have examined the Registration Statement on Form S-3ASR (File No. 333-284878) (the “Registration Statement”), including the prospectus dated February 12, 2025 included therein (the “Base Prospectus”), filed by Recursi...

On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”), as amended by the First Amendment to the Transaction Agreement dated as of November 5, 2024 (the “First ...

The information set forth in Item 3.02 of the Original Form 8-K is hereby supplemented as follows:

Consistent with the recommendation of the Company’s Board of Directors (the “Board”), a majority of the votes at the Annual Meeting were cast in favor of conducting advisory Say-on-Pay votes on an annual basis. The Board has considered t...